Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- M00227 - Provider product page
- Provider
- Boster Biological Technology
- Product name
- Anti-GAPDH Rabbit Monoclonal Antibody
- Antibody type
- Monoclonal
- Description
- Monoclonal antibody for GAPDH detection. Host: Rabbit.Size: 100ug/vial. Tested applications: Flow Cytometry, IP, IF, IHC, ICC, WB. Reactive species: Human, Mouse, Rat GAPDH information: Molecular Weight: 36053 MW; Subcellular Localization: Cytoplasm, cytosol . Nucleus . Cytoplasm, perinuclear region . Membrane . Cytoplasm, cytoskeleton . Translocates to the nucleus following S- nitrosylation and interaction with SIAH1, which contains a nuclear localization signal (By similarity). Postnuclear and Perinuclear regions.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Antibody clone number
- BH-7
- Vial size
- 100ug/vial
- Concentration
- 0.5-1mg/ml, actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.
- Storage
- At -20°C for one year. Avoid repeated freezing and thawing.
Submitted references Inhibition of Notch3/Hey1 ameliorates peribiliary hypoxia by preventing hypertrophic hepatic arteriopathy in biliary atresia progression.
Effective robotic assistive pattern of treadmill training for spinal cord injury in a rat model.
Engrailed-2 promoter hyper-methylation is associated with its downregulation in clear cell renal cell carcinoma.
Chang X, Chi S, Zhang X, Li X, Yu C, Zhou Y, Tang S
Histochemistry and cell biology 2024 Jun;161(6):461-476
Histochemistry and cell biology 2024 Jun;161(6):461-476
Effective robotic assistive pattern of treadmill training for spinal cord injury in a rat model.
Zhao BL, Li WT, Zhou XH, Wu SQ, Cao HS, Bao ZR, An LB
Experimental and therapeutic medicine 2018 Apr;15(4):3283-3294
Experimental and therapeutic medicine 2018 Apr;15(4):3283-3294
Engrailed-2 promoter hyper-methylation is associated with its downregulation in clear cell renal cell carcinoma.
Lai CY, Yu GS, Xu Y, Wu X, Heng BL, Xue YJ, Su ZX
Oncology letters 2017 Dec;14(6):6888-6894
Oncology letters 2017 Dec;14(6):6888-6894
No comments: Submit comment
No validations: Submit validation data